# Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial

Source: https://onco.cc/trials/nct07551596/  
OnCo record `nct07551596` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of balstilimab and botensilimab in colorectal cancer, run by National Cancer Institute (NCI), now recruiting.

## Summary

Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial is a phase 2, interventional study registered as NCT07551596 by National Cancer Institute (NCI), with a registry enrolment figure of 20 participants, started 2027-05-25 and due to reach its primary completion in 2029-08-28. Interventions recorded: Balstilimab; Biopsy Procedure; Biospecimen Collection; Botensilimab; Radiographic Examination. Conditions listed: Colorectal Adenocarcinoma; Stage II Colorectal Cancer AJCC v8; Stage III Colorectal Cancer AJCC v8. Primary outcome: Circulating tumor deoxyribonucleic acid (ctDNA) clearance. Colorectal eligibility wording from the registry: "* Histological confirmation of colorectal cancer (adenocarcinoma) (CRC)". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07551596
- Phase: 2
- Setting: A Phase 2 Study of Microsatellite Stable Colorectal Cancer (Stage 2 or 3) With Radiographic Occult Molecular Residual Disease Treated With Botensilimab (AGEN1181; Bot) Plus Balstilimab (AGEN2034, Bal) After Established Definitive Therapy (COMBAT Study)
- Sponsor: National Cancer Institute (NCI)
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT07551596: https://clinicaltrials.gov/study/NCT07551596

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- drugs: [Balstilimab](https://onco.cc/drugs/balstilimab/), [Botensilimab](https://onco.cc/drugs/botensilimab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07551596.json